PepGen Inc.
PEPG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PEPG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PEPG
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurological diseases, currently advancing its lead candidate PGN-EDODM1 for myotonic dystrophy type 1 (DM1) while having ceased its DMD program.
Key risk: Single product candidate risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for PepGen Inc..
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurological diseases, currently advancing its lead candidate PGN-EDODM1 for myotonic dystrophy type 1 (DM1) while having ceased its DMD program.
- PepGen has one product candidate, PGN-EDODM1, in clinical development for DM1, with a Phase 2 trial (FREEDOM2) ongoing [sec_mda · as of 2026-03-04].
- As of June 30, 2026, the company reported cash, cash equivalents, and marketable securities of $117.2 million, with an accumulated deficit of $396.7 million [sec_mda · as of 2026-08-06].
- Net loss for the six months ended June 30, 2026 was $35.6 million, compared to $53.3 million for the same period in 2025 [sec_mda · as of 2026-08-06].
- The company ceased its research and development efforts in Duchenne muscular dystrophy (DMD) in May 2025 to focus resources on PGN-EDODM1 [sec_mda · as of 2026-08-06].
- PepGen expects its existing cash to fund planned operations into the fourth quarter of 2027, but will require additional funding to complete development and commercialization [sec_mda · as of 2026-08-06].
What works
- PepGen has a focused pipeline with PGN-EDODM1 advancing in a Phase 2 trial (FREEDOM2) for DM1, a condition with significant unmet need [sec_mda · as of 2026-03-04].
- The company raised $107.6 million in net proceeds from a public offering in September 2025, extending its cash runway into Q4 2027 [sec_mda · as of 2026-08-06].
- Net loss decreased from $53.3 million to $35.6 million for the six-month period year-over-year, indicating some cost management [sec_mda · as of 2026-08-06].
What to weigh
- PepGen has a history of operating losses and an accumulated deficit of $396.7 million as of June 30, 2026, with no expectation of product revenue for at least several years [sec_mda · as of 2026-08-06].
- The company is early in development with only one clinical candidate and has conducted only two Phase 1 and three Phase 2 trials since inception, making it highly dependent on PGN-EDODM1's success [sec_mda · as of 2026-03-04].
- PepGen will need to raise substantial additional funding to complete development and commercialization, and failure to do so could force delays or discontinuation of programs [sec_mda · as of 2026-03-04].
- The company ceased its DMD program, reducing pipeline diversification and increasing reliance on a single candidate [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
PepGen's cash runway extends into Q4 2027
“We believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our currently planned operations into the fourth quarter of 2027.”
SEC MD&A · August 6, 2026
PepGen has an accumulated deficit of $396.7 million as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $396.7 million.”
SEC MD&A · August 6, 2026
PepGen ceased DMD research and development in May 2025
“Notwithstanding our decision to cease our research and development efforts in DMD, which we announced on May 28, 2025”
SEC MD&A · August 6, 2026
PepGen has only one product candidate in clinical development
“We are early in our development efforts, having conducted only two Phase 1 and three Phase 2 clinical trials since our inception”
SEC MD&A · March 4, 2026
Risks & what to watch (4)›
Key risks
- Single product candidate risk — PepGen relies solely on PGN-EDODM1 for DM1; failure would leave no pipeline [sec_mda · as of 2026-03-04].
- Need for additional funding — Cash runway only into Q4 2027; no product revenue expected for years, requiring further capital raises [sec_mda · as of 2026-08-06].
- Clinical trial uncertainty — Drug development is lengthy and expensive; PGN-EDODM1 may fail to show safety/efficacy [sec_mda · as of 2026-03-04].
- History of operating losses — Accumulated deficit of $396.7M as of June 30, 2026; net loss of $35.6M in H1 2026 [sec_mda · as of 2026-08-06].
What to watch
- Enrollment and data readouts from the Phase 2 FREEDOM2 trial for PGN-EDODM1 in DM1 [sec_mda · as of 2026-03-04].
- Cash position updates and any future capital raises, as existing runway extends only into Q4 2027 [sec_mda · as of 2026-08-06].
- Regulatory developments, including clearance to initiate trial sites in additional jurisdictions such as the US [sec_mda · as of 2026-03-04].
- Any strategic shifts or pipeline expansions following the cessation of the DMD program [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run PepGen Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PepGen Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.5 months
D/E 0.18 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 7 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
92
Total value held
$95.9M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 20,064,545 | $35.5M |
| commodore capital lp | 4,475,000 | $7.9M |
| vanguard capital management llc | 3,875,398 | $6.9M |
| viking global investors lp | 3,482,434 | $6.2M |
| laurion capital management lp | 2,750,855 | $4.9M |
| millennium management llc | 2,079,143 | $3.7M |
| kalehua capital management llc | 1,729,961 | $3.1M |
| adar1 capital management, llc | 1,607,638 | $2.8M |
| pictet asset management holding sa | 1,306,783 | $2.3M |
| blackrock, inc. | 1,277,784 | $2.3M |
Showing top 10 of 92 institutional holders of PepGen Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 6.4%
- Days to cover
- 1.7
- Shares short
- 3,438,459
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PEPG short interestFrequently asked questions
What is the AI investment thesis for PepGen Inc.?
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurological diseases, currently advancing its lead candidate PGN-EDODM1 for myotonic dystrophy type 1 (DM1) while having ceased its DMD program.
What is PepGen Inc.'s lead drug candidate?
PepGen Inc.'s most advanced tracked candidate is pgn-edo51 (Phase 2) for Duchenne Muscular Dystrophy.
Who is the CEO of PepGen Inc.?
Dr. James G. McArthur Ph.D. is the chief executive officer of PepGen Inc. (PEPG).
Where is PepGen Inc. headquartered?
PepGen Inc. (PEPG) is headquartered in Boston, MA, United States.
What therapeutic areas does PepGen Inc. focus on?
PepGen Inc. develops therapies across Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.